Compare
Repligen Corp vs BioCryst Pharmaceuticals Inc vs ADMA Biologics, Inc. vs Novavax Inc
| Latest fiscal year | Repligen Corp RGEN | BioCryst Pharmaceuticals Inc BCRX | ADMA Biologics, Inc. ADMA | Novavax Inc NVAX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $738.26M | $874.84M | $510.17M | $1.12B |
| Revenue growth (YoY) | +16.4% | +94.1% | +19.6% | +64.7% |
| Gross margin | 52.3% (computed) | n/a | 57.4% | 93.5% (computed) |
| Operating margin | 7.5% | 39.0% | 37.5% | 40.3% |
| Net margin | 6.6% | 30.2% | 28.8% | 39.2% |
| Net income | $48.89M | $263.86M | $146.93M | $440.30M |
| EPS (Diluted) | $0.86 | $1.21 | $0.60 | $2.58 |
| Operating cash flow | $117.42M | $347.37M | $50.40M | -$244.63M |
| Free cash flow | $93.90M | $344.90M | $27.82M | n/a |
| Cash & equivalents | $566.02M | $89.74M | $87.63M | $240.63M |
| Total assets | $2.95B | $514.16M | $624.24M | $1.18B |
| Total liabilities | $843.57M | $633.31M | $146.92M | $1.30B |
| Shareholders' equity | $2.11B | -$119.15M | $477.32M | -$127.75M |
| Return on year-end equity | 2.3% | n/a | 30.8% | n/a |
| Shares outstanding | 56.33M | 213.06M | 237.87M | 162.58M |
Revenue, most recent five fiscal years
| Fiscal year | Repligen Corp | BioCryst Pharmaceuticals Inc | ADMA Biologics, Inc. | Novavax Inc |
|---|---|---|---|---|
| Latest | $738.26M Ended 2025-12-31 | $874.84M Ended 2025-12-31 | $510.17M Ended 2025-12-31 | $1.12B Ended 2025-12-31 |
| 1 year earlier | $634.44M Ended 2024-12-31 | $450.71M Ended 2024-12-31 | $426.45M Ended 2024-12-31 | $682.16M Ended 2024-12-31 |
| 2 years earlier | $632.36M Ended 2023-12-31 | $331.41M Ended 2023-12-31 | $258.21M Ended 2023-12-31 | $983.71M Ended 2023-12-31 |
| 3 years earlier | $801.54M Ended 2022-12-31 | $270.83M Ended 2022-12-31 | $154.08M Ended 2022-12-31 | $1.98B Ended 2022-12-31 |
| 4 years earlier | $670.53M Ended 2021-12-31 | $157.17M Ended 2021-12-31 | $80.94M Ended 2021-12-31 | $1.15B Ended 2021-12-31 |